Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 35, Issue 20, Pages 2251-+Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2017.73.0143
Keywords
-
Categories
Funding
- AstraZeneca
- Puma Biotechnology
- Loxo
- Genentech (Inst)
- Novartis
- Merck
- Biomarin
- GlaxoSmithKline
- ProNAi
- Karyopharm Therapeutics
- Spectrum Pharmaceuticals
- Celgene
- Millennium
- Janssen
- Critical Outcome Technologies
- Cancer Research UK [11566] Funding Source: researchfish
Ask authors/readers for more resources
PurposeAKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity of AKT inhibition in AKT-mutant cancers.Patients and MethodsFifty-eight patients with advanced solid tumors were treated. The primary end point was safety; secondary end points were progression-free survival (PFS) and response according to Response Evaluation Criteria in Solid Tumors (RECIST). Tumor biopsies and plasma cell-free DNA (cfDNA) were collected in the majority of patients to identify predictive biomarkers of response.ResultsIn patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively. In an exploratory biomarker analysis, imbalance of the AKT1 E17K-mutant allele, most frequently caused by copy-neutral loss-of-heterozygosity targeting the wild-type allele, was associated with longer PFS (hazard ratio [HR], 0.41; P = .04), as was the presence of coincident PI3K pathway hotspot mutations (HR, 0.21; P = .045). Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS (HR, 0.18; P = .004) and response (P = .025). Responses were not restricted to patients with detectable AKT1 E17K in pretreatment cfDNA. The most common grade 3 adverse events were hyperglycemia (24%), diarrhea (17%), and rash (15.5%).ConclusionThis study provides the first clinical data that AKT1 E17K is a therapeutic target in human cancer. The genomic context of the AKT1 E17K mutation further conditioned response to AZD5363.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available